Rifampin Pharmacokinetics and Safety in Preterm and Term Infants

Rifampin is active against methicillin-resistant staphylococcal species and tuberculosis (TB). We performed a multicenter, prospective pharmacokinetic (PK) and safety study of intravenous rifampin in infants of

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antimicrobial agents and chemotherapy 2019-06, Vol.63 (6)
Hauptverfasser:	Smith, P Brian, Cotten, C Michael, Hudak, Mark L, Sullivan, Janice E, Poindexter, Brenda B, Cohen-Wolkowiez, Michael, Boakye-Agyeman, Felix, Lewandowski, Andrew, Anand, Ravinder, Benjamin, Jr, Daniel K, Laughon, Matthew M
Format:	Artikel
Sprache:	eng
Schlagworte:	Female Gestational Age Humans Infant Infant, Newborn Infant, Premature Infant, Premature - metabolism Male Pharmacology Prospective Studies Rifampin Rifampin - adverse effects Rifampin - pharmacokinetics Rifampin - therapeutic use Staphylococcal Infections - drug therapy Staphylococcal Infections - metabolism Tuberculosis - drug therapy Tuberculosis - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Rifampin is active against methicillin-resistant staphylococcal species and tuberculosis (TB). We performed a multicenter, prospective pharmacokinetic (PK) and safety study of intravenous rifampin in infants of
ISSN:	0066-4804 1098-6596 1098-6596
DOI:	10.1128/AAC.00284-19